IL201105A0 - Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor - Google Patents
Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptorInfo
- Publication number
- IL201105A0 IL201105A0 IL201105A IL20110509A IL201105A0 IL 201105 A0 IL201105 A0 IL 201105A0 IL 201105 A IL201105 A IL 201105A IL 20110509 A IL20110509 A IL 20110509A IL 201105 A0 IL201105 A0 IL 201105A0
- Authority
- IL
- Israel
- Prior art keywords
- serotonin
- receptor
- respond
- modulation
- compounds suitable
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 229940076279 serotonin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104806 | 2007-03-23 | ||
| PCT/EP2008/053387 WO2008116831A1 (en) | 2007-03-23 | 2008-03-20 | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL201105A0 true IL201105A0 (en) | 2010-05-17 |
Family
ID=39620293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL201105A IL201105A0 (en) | 2007-03-23 | 2009-09-22 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8242102B2 (enExample) |
| EP (1) | EP2139880B1 (enExample) |
| JP (1) | JP5538907B2 (enExample) |
| KR (1) | KR20090128426A (enExample) |
| CN (1) | CN101679351B (enExample) |
| AR (1) | AR068381A1 (enExample) |
| AT (1) | ATE524456T1 (enExample) |
| AU (1) | AU2008231787A1 (enExample) |
| BR (1) | BRPI0809081A2 (enExample) |
| CA (1) | CA2681030C (enExample) |
| CO (1) | CO6230989A2 (enExample) |
| CR (1) | CR11039A (enExample) |
| DO (1) | DOP2009000228A (enExample) |
| EC (1) | ECSP099651A (enExample) |
| ES (1) | ES2373617T3 (enExample) |
| IL (1) | IL201105A0 (enExample) |
| MX (1) | MX2009010243A (enExample) |
| NZ (1) | NZ579735A (enExample) |
| PE (1) | PE20091187A1 (enExample) |
| RU (1) | RU2009139073A (enExample) |
| TW (1) | TW200940524A (enExample) |
| UA (1) | UA97837C2 (enExample) |
| UY (1) | UY31326A (enExample) |
| WO (1) | WO2008116831A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| US20130343993A1 (en) * | 2012-01-06 | 2013-12-26 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
| WO2017157929A1 (en) * | 2016-03-14 | 2017-09-21 | AbbVie Deutschland GmbH & Co. KG | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| CN109503449A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1219618A4 (en) * | 1999-09-02 | 2002-09-18 | Wakunaga Pharma Co Ltd | QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT |
| JP2003277416A (ja) | 2002-03-22 | 2003-10-02 | Daiyanitorikkusu Kk | 糖類を含むアクリルアミド水溶液 |
| ATE398108T1 (de) * | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
| US20050165006A1 (en) | 2002-04-03 | 2005-07-28 | Dae-Yoon Chi | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same |
| PL374401A1 (en) | 2002-06-05 | 2005-10-17 | F.Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7227023B2 (en) | 2003-04-30 | 2007-06-05 | Wyeth | Quinoline 3-amino chroman derivatives |
| GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| CA2616473A1 (en) | 2005-07-27 | 2007-03-08 | F. Hoffmann-La Roche Ag | 4-aryloxy quinoline derivatives as 5-ht6 modulators |
| GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| ES2389958T3 (es) | 2007-03-21 | 2012-11-05 | Glaxo Group Limited | Uso de derivados de quinolina en el tratamiento del dolor |
-
2008
- 2008-03-20 NZ NZ579735A patent/NZ579735A/en not_active IP Right Cessation
- 2008-03-20 BR BRPI0809081A patent/BRPI0809081A2/pt not_active IP Right Cessation
- 2008-03-20 JP JP2009554034A patent/JP5538907B2/ja not_active Expired - Fee Related
- 2008-03-20 CN CN200880017192.XA patent/CN101679351B/zh not_active Expired - Fee Related
- 2008-03-20 KR KR1020097019918A patent/KR20090128426A/ko not_active Withdrawn
- 2008-03-20 AU AU2008231787A patent/AU2008231787A1/en not_active Abandoned
- 2008-03-20 RU RU2009139073/04A patent/RU2009139073A/ru not_active Application Discontinuation
- 2008-03-20 ES ES08735447T patent/ES2373617T3/es active Active
- 2008-03-20 EP EP08735447A patent/EP2139880B1/en active Active
- 2008-03-20 AT AT08735447T patent/ATE524456T1/de not_active IP Right Cessation
- 2008-03-20 MX MX2009010243A patent/MX2009010243A/es active IP Right Grant
- 2008-03-20 WO PCT/EP2008/053387 patent/WO2008116831A1/en not_active Ceased
- 2008-03-20 CA CA2681030A patent/CA2681030C/en not_active Expired - Fee Related
- 2008-03-20 UA UAA200910698A patent/UA97837C2/ru unknown
- 2008-03-23 US US12/532,407 patent/US8242102B2/en not_active Expired - Fee Related
- 2008-09-02 TW TW097133636A patent/TW200940524A/zh unknown
- 2008-09-08 AR ARP080103894A patent/AR068381A1/es not_active Application Discontinuation
- 2008-09-08 PE PE2008001568A patent/PE20091187A1/es not_active Application Discontinuation
- 2008-09-08 UY UY0001031326A patent/UY31326A/es not_active Application Discontinuation
-
2009
- 2009-09-22 CO CO09103181A patent/CO6230989A2/es not_active Application Discontinuation
- 2009-09-22 IL IL201105A patent/IL201105A0/en unknown
- 2009-09-22 DO DO2009000228A patent/DOP2009000228A/es unknown
- 2009-09-23 CR CR11039A patent/CR11039A/es unknown
- 2009-09-23 EC EC2009009651A patent/ECSP099651A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP099651A (es) | 2009-10-30 |
| EP2139880A1 (en) | 2010-01-06 |
| KR20090128426A (ko) | 2009-12-15 |
| JP2010521520A (ja) | 2010-06-24 |
| UY31326A (es) | 2009-11-10 |
| CN101679351B (zh) | 2015-01-07 |
| CO6230989A2 (es) | 2010-12-20 |
| CA2681030A1 (en) | 2008-10-02 |
| PE20091187A1 (es) | 2009-09-06 |
| US8242102B2 (en) | 2012-08-14 |
| UA97837C2 (ru) | 2012-03-26 |
| DOP2009000228A (es) | 2009-10-15 |
| MX2009010243A (es) | 2009-12-14 |
| WO2008116831A1 (en) | 2008-10-02 |
| CA2681030C (en) | 2015-01-13 |
| AR068381A1 (es) | 2009-11-11 |
| ES2373617T3 (es) | 2012-02-07 |
| CN101679351A (zh) | 2010-03-24 |
| EP2139880B1 (en) | 2011-09-14 |
| CR11039A (es) | 2010-02-09 |
| TW200940524A (en) | 2009-10-01 |
| JP5538907B2 (ja) | 2014-07-02 |
| HK1139933A1 (en) | 2010-09-30 |
| ATE524456T1 (de) | 2011-09-15 |
| RU2009139073A (ru) | 2011-04-27 |
| US20110009380A1 (en) | 2011-01-13 |
| NZ579735A (en) | 2012-02-24 |
| BRPI0809081A2 (pt) | 2019-09-24 |
| AU2008231787A1 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200909075B (en) | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| IL266471A (en) | Apoptosis modulators with controlled release and methods for treating ear-related disorders | |
| IL241791A0 (en) | Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders | |
| LT2364142T (lt) | 5-ht2a serotonino receptoriaus moduliatoriaus kompozicijos, naudotinos su juo susijusių sutrikimų gydymui | |
| IL201107A0 (en) | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| ZA201107569B (en) | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| SI2229369T1 (sl) | Derivati 6,7-dialkoksi kinazolina, uporabni za zdravljenje motenj, povezanih z rakom | |
| IL207914A0 (en) | Azaindole compounds for treatment of central nervous system disorders | |
| HUE045270T2 (hu) | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére | |
| IL201105A0 (en) | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| ZA200703059B (en) | 6-Amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| IL225745A0 (en) | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds are suitable for the treatment of disorders that respond to dopamine 3d receptor regulation | |
| ZA200705008B (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| ZA201204391B (en) | Compounds for the treatment of neurologic disorders | |
| IL205468A0 (en) | 1, 2, 4, - triazin - 3, 5 - dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor | |
| ZA201003594B (en) | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| HK1141018A (en) | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| EP2578206A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM | |
| EP2240024A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| HK1130771A (en) | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor | |
| HK1144811A (en) | Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
| HK1106520A (en) | Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |